Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
5.81
+0.08 (1.40%)
Jul 3, 2025, 1:00 PM - Market closed
Astria Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
78
Market Cap
327.88M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ATXS News
- 3 days ago - Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 17 days ago - Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit - Business Wire
- 22 days ago - Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress - Business Wire
- 4 weeks ago - Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress - Business Wire
- 5 weeks ago - Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference - Business Wire
- 6 weeks ago - Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop - Business Wire
- 6 weeks ago - Astria Therapeutics to Present at Upcoming Eastern Allergy Conference - Business Wire
- 7 weeks ago - Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update - Business Wire